Back to Directory

Curileum Discovery

Small-molecule therapies for colorectal cancer prevention and gastrointestinal disease

Curileum Discovery is a biopharmaceutical company developing oral small-molecule therapies for gastrointestinal disease and colorectal cancer prevention. Its lead candidate is a pan-PPAR agonist designed to influence abnormal cell production in the intestinal lining and reduce precancerous polyp formation.

The company is advancing preclinical development towards studies in familial adenomatous polyposis, an inherited condition associated with colorectal cancer risk, while also investigating applications in inflammatory bowel disease.

Company Notes

Previously Known As
Cibagen